Rare lephants
Screener

Cavitation Technologies, Inc.

CVAT ·Consumer Defensive, Farm Products, United States
Analysis › Company Overview

Business Overview: Cavitation Technologies, Inc. (OTCQB: CVAT)

Executive Summary

Cavitation Technologies, Inc. ("CTi") is a Camarillo, California-based technology company that develops and licenses equipment built around its proprietary "Nano Reactor®" platform, a hydrodynamic cavitation technology designed to intensify chemical and physical reactions in industrial liquids, reducing processing time, lowering operating costs, and improving yields across a range of liquid-processing industries. The company's most commercially mature application has historically been vegetable oil refining, where CTi reports having shipped more than 200 Nano Reactor systems domestically and internationally for soybean, rapeseed and palm oil refining customers — a genuine, long-running industrial technology business, not a pre-revenue concept.

However, CTi's financial trajectory has deteriorated sharply. Fiscal year 2025 (ended June 30, 2025) revenue was just $203,000, down from $1.36 million in fiscal 2024, and more recent trailing-twelve-month revenue has fallen to approximately $11,000 — an extraordinary decline reflecting the company's October 2024 decision to assign its core vegetable-oil-refining patent to its strategic partner Desmet (a leading global vegetable-oil processing equipment supplier) in exchange for an $880,000 payment, effectively monetizing and outsourcing its flagship product line rather than continuing to sell and service it directly. With only three full-time employees and heavy reliance on consultants, CTi today functions primarily as an intellectual-property licensor and technology-development shop rather than an operating equipment manufacturer, and management has explicitly disclosed substantial doubt about the company's ability to continue as a going concern.

For an investor, the key fact is that CTi is a real company with a real, patented and commercially proven core technology and a multi-decade operating history, but it has effectively sold off its primary cash-generating product line and is now pursuing a thin, early-stage set of adjacent applications (water treatment, agricultural remediation, beverage processing) with negligible current revenue and acute financial distress.

1. Core Business Model & How They Work

CTi's Nano Reactor technology uses controlled hydrodynamic cavitation — the formation and violent collapse of microscopic vapor bubbles within a flowing liquid — to intensify chemical reactions such as degumming, neutralization, and bleaching in vegetable oil refining, without the heat or chemical dosing intensity of conventional refining methods. The company's historical model was to sell or license Nano Reactor systems directly to oil refiners and equipment integrators; its October 2024 patent assignment to Desmet converted that relationship into a licensing/royalty-style arrangement where Desmet, not CTi, now owns and presumably commercializes the core intellectual property going forward.

Beyond vegetable oil, CTi has been attempting to extend the underlying cavitation platform into adjacent liquid-processing markets: a Low Pressure Nano Reactor (LPN™) for treating produced and frac water in oil and gas operations, agricultural water remediation systems (recently installed at Canadian greenhouse operations), and a licensing arrangement with Alchemy Beverages for alcoholic beverage processing devices using the cavitation platform. The company is also developing an emerging "Hydro-Plasma" technology that combines cavitation with cold plasma for water treatment applications — an earlier-stage R&D effort rather than a commercial product.

Key Operational Drivers

  1. Monetization of Core IP via the Desmet Transaction — assigning the vegetable-oil-refining patent to Desmet for $880,000 in October 2024 converted CTi's flagship, revenue-generating product line into a one-time cash payment plus (presumably) some ongoing licensing economics, fundamentally shrinking the company's direct commercial footprint.
  2. Diversification Attempts into Water Treatment and Beverage Processing — the LPN™ water-treatment product, Canadian greenhouse agricultural remediation installations, and the Alchemy Beverages licensing deal represent CTi's attempt to find new commercial applications for its cavitation platform outside of oil refining, but none has yet generated meaningful revenue.
  3. Minimal Fixed Cost Base — with only three full-time employees and heavy reliance on outside consultants, CTi has structured itself to survive on very low revenue, though this also limits its capacity to execute a broad commercialization push across multiple new markets simultaneously.
  4. Emerging Hydro-Plasma R&D — combining cold plasma with cavitation for water treatment represents a next-generation technology bet, but it remains in early development with no disclosed near-term commercialization timeline.
  5. Going-Concern Financial Constraint — explicit going-concern doubt in the company's financial statements means every strategic decision is now shaped by an acute need for cash, limiting CTi's ability to invest in sales, marketing or further R&D without additional financing or licensing deals.

2. Business Segments

CTi operates as a single reportable segment: the development and licensing of hydrodynamic cavitation ("Nano Reactor") technology, applied across vegetable oil refining (now largely transferred to Desmet), water treatment, agricultural remediation, and beverage processing.

3. Product Portfolio

  • Nano Reactor® — core hydrodynamic cavitation technology for vegetable oil refining (IP now assigned to Desmet); over 200 systems shipped historically
  • Low Pressure Nano Reactor (LPN™) — water treatment system for produced/frac water in oil and gas operations
  • Agricultural water remediation systems — recently installed at Canadian greenhouse operations
  • Alchemy Beverages licensing — cavitation-based alcoholic beverage processing devices
  • Hydro-Plasma technology — early-stage R&D combining cavitation and cold plasma for water treatment

4. Competitive Landscape

In its historical core market, CTi's technology competed against conventional chemical/thermal refining methods and larger process-equipment suppliers; Desmet itself — now the owner of CTi's core patent — is one of the largest global suppliers of vegetable oil processing equipment, alongside companies such as Alfa Laval and GEA Group, both of which offer competing process-intensification and separation technologies to the same oilseed-processing customer base. In water treatment, CTi's LPN™ system competes against a wide range of established produced-water treatment technologies offered by oilfield services companies. CTi's competitive position in all of these markets is now that of a small technology licensor rather than a direct equipment competitor, since its most commercially proven application (vegetable oil) has been transferred to a much larger partner.

5. Strategic Strengths & Risks

Strengths: a genuinely proven, patented core technology platform with a 200+ system commercial installation history; an $880,000 cash infusion and ongoing relationship from the Desmet transaction; and several early-stage diversification efforts (water treatment, beverage processing, agricultural remediation) that could eventually provide new revenue streams if any gains commercial traction.

Risks: revenue has collapsed to negligible levels (trailing-twelve-month revenue of roughly $11,000, down nearly 99% year over year), explicit going-concern doubt disclosed by management, and the company's most commercially validated product line (vegetable oil refining) has effectively been transferred to Desmet, leaving CTi dependent on unproven, early-stage applications for future growth; an extremely thin operating structure (three full-time employees) that limits execution capacity; and a micro-cap market value (~$9 million) and sub-penny share price that reflect significant market skepticism about the company's near-term viability.

6. Financial Overview

Fiscal year 2025 (ended June 30, 2025) revenue was $203,000, down sharply from $1.36 million in fiscal 2024, with the primary remaining revenue source being reactor sales to strategic partner Desmet. More recent trailing-twelve-month revenue has fallen further to approximately $11,000, a 98.7% year-over-year decline, alongside a net loss of approximately $1.19 million. The company's market capitalization is approximately $9.1 million, with shares trading around $0.03. Management has disclosed substantial doubt about the company's ability to continue as a going concern, and the October 2024 patent assignment to Desmet for $880,000 provided a one-time cash benefit that does not appear to have been replaced by a recurring revenue stream.

7. Summary Conclusion

Cavitation Technologies is a long-standing, legitimately operating technology company with a real, patented, commercially proven core innovation in hydrodynamic cavitation — but it has effectively monetized and handed off its primary commercial product line to a much larger partner (Desmet) and is now pursuing a thin set of unproven diversification efforts (water treatment, beverage processing) against a backdrop of explicit going-concern risk and near-zero current revenue. This is a distressed micro-cap with real underlying technology and IP history, not a pure blank-check shell, but its near-term financial viability is genuinely in question, and any investment thesis depends almost entirely on whether its diversification bets can generate real revenue before its cash position is exhausted.